Ambu reports slight decline in first-half sales
This article was originally published in Clinica
Intensified price competition in the US and a delay in the launch of two new products resulted in declining revenues during the first half, says Danish company Ambu. In the six months to the end of March, sales fell 2% to DKr 106.5 million ($18 million). Net profits rose to DKr 5 million from DKr 4.6 million in the previous year.
You may also be interested in...
A recent Department of Health and Human Services proposal to review regulations every 10 years may mean good things for the device industry, said David Hoffmeister, partner, Wilson Sonsini Goodrich & Rosati.
Aker BioMarine seeks supplement firms to use its EPA/DHA innovation bound by lysophosphatidylcholine to enable the fatty acids to pass through the blood-brain and blood-retinal barriers and boost of eye and brain health benefits. It will submit an NDI notificaion in the US during 2022.
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.